Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Eligibility for PCSK9 Inhibitors After ACS

J Am Heart Assoc; ePub 2017 Nov 9; Gencer, et al

Recommendations made by the American College of Cardiology (ACC) guidelines would lead to 5-fold higher eligibility rates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors compared to the European Society of Cardiology/European Atherosclerosis Society consensus statement in patients with acute coronary syndrome (ACS), a recent study found. A prospective Swiss cohort of 2,023 patients hospitalized for ACS between 2009 and 2014 with available data for low-density lipoprotein cholesterol (LDL-C) and lipid-lowering therapy at 1 year was analyzed. Researchers found:

  • At 1 year, 94.3% of patients were treated with a statin, and 35.8% of patients had on-target LDL-C levels.
  • The proportion of patients who would be eligible for PCSK9 inhibitors at 1 year was 13.4% using ACC criteria and 2.7% using European Society of Cardiology/European Atherosclerosis Society criteria.
  • Patients with possible or probable/definite familial hypercholesterolemia (FH) were more eligible for PCSK9 inhibitors compared with their non-FH counterparts.

Citation:

Gencer B, Koskinas KC, Räber L, et al. Eligibility for PCSK9 inhibitors according to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines after acute coronary syndromes. [Published online ahead of print November 9, 2017]. J Am Heart Assoc. doi:10.1161/JAHA.117.006537.

This Week's Must Reads

Length of Stay & Early Discharge After Acute MI, Am J Cardiol; ePub 2017 Nov 22; Tran, et al

SBP Response and Discordant Trial Results, J Am Heart Assoc; ePub 2017 Nov 13; Huang, et al

Racial Differences in Natriuretic Peptide Levels, JAMA Cardiol; ePub 2017 Nov 22; Bajaj, et al

Gender Disparities in Cardiovascular Testing, J Am Heart Assoc; ePub 2017 Nov 29; Daugherty, et al

FDA Approves EKG Device for Apple Watch, AliveCor news release; 2017 Nov 30

Must Reads in Hypercholesterolemia

LDL-C Lowering with Evolocumab in Patients with PAD, Circulation; ePub 2017 Nov 13; Bonaca, et al

Does Evolocumab Lower Lipoprotein Particles?, Am J Cardiol; ePub 2017 Nov 8; Toth, et al

PCSK9 Inhibition & Neurocognitive Impairment, Circulation; ePub 2017 Nov 16; Mefford, et al

Eligibility for PCSK9 Inhibitors After ACS, J Am Heart Assoc; ePub 2017 Nov 9; Gencer, et al

CV Risk & Statins After MI in Young Adults, J Am Coll Cardiol; ePub 2017 Nov 14; Singh, et al